Price$0.14-0.01 (-3.70%)
01:30 PM07:45 PM
News · 26 weeks71+75%
2026-01-182026-07-12
Mix3790d
- SEC Filings23(62%)
- Other9(24%)
- Offering3(8%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Picard Medical Inc.DEFA14A - Picard Medical, Inc. (0002030617) (Filer)
- PRArtificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart ProgramTUCSON, Ariz., July 15, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard Medical" or the "Company"), parent company of SynCardia Systems, LLC ("SynCardia"), maker of the world's first and only total artificial heart approved by the U.S. Food and Drug Administration ("FDA") and Health Canada, today announced the publication of an independent commentary in Artificial Organs examining the Company's next-generation Emperor platform, which combines the Emperor Drive with the SynCardia Total Artificial Heart ("STAH"), and its role in the continued evolution of mechanical heart replacement technology. The article, titled "A New Chapter in the Quest for a Fully Implantable Artifi
- PRPicard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual MeetingTUCSON, Ariz., July 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard Medical" or the "Company"), parent company of SynCardia Systems, LLC ("SynCardia"), maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration and Health Canada, today announced the availability of its pre-recorded presentation in advance of the Company's 2026 Annual Meeting of Stockholders, scheduled for July 17, 2026. The presentation provides stockholders with an overview of the Company's recent business performance, product development progress, manufacturing initiatives, and the proposals to be considered at the Annual Meeting. "Despite recent leader
- SECAmendment: Picard Medical Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Other Events8-K/A - Picard Medical, Inc. (0002030617) (Filer)
- SECSEC Form DEFA14A filed by Picard Medical Inc.DEFA14A - Picard Medical, Inc. (0002030617) (Filer)
- SECSEC Form 425 filed by Picard Medical Inc.425 - Picard Medical, Inc. (0002030617) (Subject)
- SECPicard Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Picard Medical, Inc. (0002030617) (Filer)
- SECSEC Form 425 filed by Picard Medical Inc.425 - Picard Medical, Inc. (0002030617) (Subject)
- SECPicard Medical Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Picard Medical, Inc. (0002030617) (Filer)
- PRPicard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual MeetingTUCSON, Ariz., July 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard Medical" or the "Company"), parent company of SynCardia Systems, LLC ("SynCardia"), maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration and Health Canada, today announced the availability of its pre-recorded presentation in advance of the Company's 2026 Annual Meeting of Stockholders, scheduled for July 17, 2026. The presentation provides stockholders with an overview of the Company's recent business performance, product development progress, manufacturing initiatives, and the proposals to be considered at the Annual Meeting. "Despite recent leader
- SECPicard Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Picard Medical, Inc. (0002030617) (Filer)
- SECSEC Form DEF 14A filed by Picard Medical Inc.DEF 14A - Picard Medical, Inc. (0002030617) (Filer)
- PRPicard Medical Announces Leadership TransitionTUCSON, Ariz., June 24, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard Medical" or the "Company"), parent company of SynCardia Systems, LLC ("SynCardia"), maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration and Health Canada, today announced a leadership transition. Patrick NJ Schnegelsberg has stepped down as Chief Executive Officer and as a member of the Company's Board of Directors, effective June 18, 2026. Mr. Schnegelsberg's departure was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. Effective June 18, 2026, the Board appointed Richard Fang,
- SECPicard Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Picard Medical, Inc. (0002030617) (Filer)
- PRPicard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026TUCSON, Ariz., June 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard Medical" or the "Company"), parent company of SynCardia Systems, LLC ("SynCardia"), maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration and Health Canada, today announced that SynCardia researchers will present new preclinical data from the Company's next generation Emperor Total Artificial Heart program and new clinical outcomes research involving patients supported with the SynCardia Total Artificial Heart at the American Society for Artificial Internal Organs (ASAIO) 2026 Annual Conference, taking place June 18-21, 2026, in New Orleans, Louisiana
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Picard Medical Inc.SCHEDULE 13G/A - Picard Medical, Inc. (0002030617) (Subject)
- PRPicard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures — — Advancing second-generation Emperor TAH development toward a fully implantable system — TUCSON, Ariz., June 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company" or "Picard Medical"), parent company of SynCardia Systems LLC, maker of the world's first and only total artificial heart approved by both the U.S. FDA and Health Canada, today announced the successful completion of an acute in vivo implant study series using the Company's next-generation Emperor Total Artificial Heart ("Emperor TAH" or "Emperor") Platform at the University of Arizona an
- SECPicard Medical Inc. filed SEC Form 8-K: Leadership Update8-K - Picard Medical, Inc. (0002030617) (Filer)
- SECSEC Form 424B3 filed by Picard Medical Inc.424B3 - Picard Medical, Inc. (0002030617) (Filer)
- SECSEC Form EFFECT filed by Picard Medical Inc.EFFECT - Picard Medical, Inc. (0002030617) (Filer)
- SECPicard Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Picard Medical, Inc. (0002030617) (Filer)
- PRPICARD MEDICAL, INC. Issues Letter to ShareholdersTUCSON, Ariz., May 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company" or "Picard Medical"), parent company of SynCardia Systems LLC, maker of the world's first and only total artificial heart approved by both the U.S. FDA and Health Canada, today issued the following letter to shareholders: Dear Shareholders, Picard Medical, Inc. (NYSE:PMI) ("Picard Medical" or the "Company"), the parent company of SynCardia Systems LLC, is focused on advancing life-saving technologies for patients with end-stage heart failure while building long-term value for our shareholders. That mission continues to guide our strategy, and the progress we have made since 2025 — commercially,
- SECPicard Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Picard Medical, Inc. (0002030617) (Filer)
- PRPicard Medical / SynCardia Reports First Quarter 2026 Financial Results– Gross profit turns positive; Company executes significant debt reduction – -- Responds to NYSE American continued listing notice - TUCSON, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard Medical" or the "Company"), parent company of SynCardia Systems, LLC, ("SynCardia") maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, reported financial results for the first quarter ended March 31, 2026. "We continue to make progress across both our commercial and strategic priorities," said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical Inc. "During and the quarter, we improved gross margin perform
- SECSEC Form S-1 filed by Picard Medical Inc.S-1 - Picard Medical, Inc. (0002030617) (Filer)
PMI FAQ
6 questionsWhere does PMI stock trade?
Picard Medical Inc. (PMI) is listed on AMEX.What sector and industry is PMI in?
Picard Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Picard Medical Inc. go public?
Picard Medical Inc. (PMI) completed its IPO in 2025.What are analysts saying about PMI?
Picard Medical Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Neutral on 2026-05-18.What companies are similar to PMI?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PMI side-by-side with any of them on Quantisnow.How can I track PMI on Quantisnow?
Quantisnow aggregates Picard Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PMI to receive live email and push alerts on every new disclosure.